

# ASX Announcement

## 22 April 2021

Cogstate Limited  
ABN 80 090 975 723

Suite 117  
425 Smith Street  
Fitzroy Victoria 3065  
Australia

P +61 3 9664 1300  
F +61 3 9664 1301  
W cogstate.com

### Business Update and March 2021 Quarter Cashflow (All figures in US\$)

Cogstate Ltd (ASX:CGS) has today released a business update and its Appendix 4C – Quarterly Cash Flow statement for the quarter ended 31 March 2021 (3Q21).

Highlights:

- **Group revenue**
  - 3Q21 \$8.8m, up 40% compared to previous corresponding period (PCP)\*.
  - FY21 year-to-date \$22.7m (a record 9mth result), up 51% compared to PCP.
- **Clinical Trials:**
  - Revenue \$7.3m, up 26% compared to PCP.
  - Sales contracts executed in 3Q21 \$13.3m (a record for a 3Q), up 24% compared to PCP.
  - Revenue backlog in Clinical Trials was \$55.7m as at 31 March 2021
- **Healthcare:**
  - Revenue \$1.5m, up 217% compared to PCP\*.
  - Revenue backlog in Healthcare was \$24.0m as at 31 March 2021.
- **Total Contracted future revenue** \$79.7m at 31-Mar-21 vs \$74.8m at 31-Dec-20 vs \$42.1m at 31-Mar-20.
- **Cash Flow/Balance Sheet:** 3Q21 total cash outflow of -\$1.2m (net operating cash outflow of -\$1.3m, with a \$2.0m increase in receivables to \$7.5m). Net cash as at 31-Mar-21 was \$17.6m\*\*.
- **FY21 outlook:** Cogstate recorded a profit before tax during 3Q21 and expects to report a profit before tax for the full year ending 30 June 2021

	3Q21 US\$m	2Q21 US\$m	3Q20* (PCP) US\$m	3Q21 vs 3Q20 %
Total revenue from ordinary activities	8.83	7.72	6.32	39.6%
- Clinical Trials revenue	7.26	6.82	5.74	26.4%
- Healthcare revenue	1.51	0.86	0.48	216.9%
- Research revenue	0.06	0.05	0.10	(45.8%)
Sales contracts executed	13.3	14.3	10.7	24.2%
Contracted future revenue	79.7	74.8	42.1	89.3%
Net operating cash flow	-1.3	15.5	0.06	(2,267%)
Total cash flow	-1.2	14.0	0.2	(700%)
Net cash balance at end of period**	17.6	18.5	7.1	147.9%
Trade receivables	7.5	5.5	7.3	2.7%

\*3Q20 numbers have been restated following a review of the application of the Group's accounting policy in respect of revenue relating to the grant of licences, provision of services and the provision of server access, in accordance with the requirements of AASB 15 Revenue from Contracts with Customers. These changes were implemented with the 1H21 result (see explanatory notes and reconciliation table on p.2 of this release).

\*\* Calculated as gross cash less borrowings

## Explanatory Notes

1. **Sales contracts:** In the Clinical Trials division, Cogstate enters into contracts (“sales contracts”) with both pharmaceutical and biotechnology companies for the provision of Cogstate technology and services, for use in clinical research trials, to determine the extent to which their investigational compound is impacting the cognition of the patient population. The contract value will differ for each clinical trial, depending upon the scope of the technology and services provided by Cogstate, as well as the complexity and length of the trial. An increase in the total value of sales contracts executed will increase the revenue backlog and will, over time, result in an increase to revenue recognised by Cogstate.
2. **Calculation of revenue from Clinical Trials division:** Revenue from sales contracts is recognised over the life of the contract. The length of a clinical trial can vary from several months for a phase 1 study and up to 4-5 years for a phase 3 study. Revenue is recognised based upon achievement of pre-determined milestones. During each period, revenue may be recognised from (i) contracts in the backlog at the beginning of the period, as well as (ii) sales contracts executed during the period. Usually there is a time lag between an increase or decrease in the level of sales contracts executed and a corresponding change to recognised revenue.
3. **Contracted future revenue backlog:** Executed sales contract values that have not yet been recognised as revenue at period end are referred to as “contracted future revenue”. The revenue from these contracts will be recognised upon achievement of pre-determined milestones throughout the clinical trials. The contracted future revenue figure provides insight into future revenue performance.
4. **Healthcare revenue:** Cogstate has developed tools specifically designed to aid healthcare professionals, in general and specialist practice medicine, with objective assessments of cognition in patients. Cogstate’s Healthcare offering includes the system branded as Cognigram™, a medical device which allows for regular and standardised testing to assist in the early detection of cognitive decline that could be related to a range of factors, including neurodegenerative diseases such as Alzheimer’s disease. On 26 October 2020, Cogstate announced an exclusive global licensing agreement with pharmaceutical company Eisai (was previously just Japan), under which Eisai will market Cogstate technology as digital cognitive assessment tools targeting physicians, corporations, municipalities and also directly to consumers.

Due to the significance of the global licensing agreement, the group announced in its 1H21 results that it had reviewed the application of its accounting policy in respect of revenue relating to the grant of licences, provision of supporting services and the provision of server access, in accordance with the requirements of AASB 15 Revenue from Contracts with Customers.

The group considers that recognising the upfront cash payments received From Eisai (\$1m in Dec 19 for Japan and \$15m in Dec 20 for Global (ex Japan)) as revenue on a straight-line basis over the licence periods better reflects its performance in providing access to the licences, continuing support services and servers. As required by the accounting standards, this change is applied retrospectively, and as a result, the group has restated comparative figures. This resulted in a \$0.03m increase in Healthcare revenue in 3Q20 from a reported \$0.45m to a restated \$0.48m. This restatement has no impact on cash. See reconciliation table below.

	(Restated)		(As Reported)
	3Q20	Adjustment	3Q20
	US\$		US\$
Healthcare Revenue	0.48	0.03	0.45

The group will also recognise US\$10m of minimum royalty payments associated with the initial Global (ex-Japan) licence on a straight-line basis over 6 years (5 year term +12mths to commence). Actual cash royalties paid in each period will be the higher of (i) royalty amount calculated based on sales of product or (ii) minimum annual royalty.

## Revenue

Cogstate reported total revenue of \$8.8 million for 3Q21, up 40% on pcp (3Q20 \$6.3m) and 14% higher than the prior quarter (2Q20 \$7.7m).

Total revenue, year-to-date (YTD) of \$22.68 million is up 51% compared to the same time last year and is a record 9-month result for Cogstate (previous record \$21.6m at 31 March 2018).

Revenue	3Q21	3Q20	Variance	FY21 YTD	FY20 YTD	Variance
	US\$ m	US\$ m	%			
Clinical Trials	7.26	5.74	26%	19.84	14.00	42%
Healthcare	1.51	0.48	215%	2.66	0.81	228%
Research	0.06	0.10	(40%)	0.18	0.24	(25%)
<b>Total Revenue</b>	<b>8.83</b>	<b>6.32</b>	<b>40%</b>	<b>22.68</b>	<b>15.05</b>	<b>51%</b>

Clinical Trials revenue in 3Q21 was \$7.3m, up 26.4% on pcp and 6.5% higher than 2Q21, benefitting from the substantial increase in new Clinical Sales contracts executed in recent periods. Revenue recognition during the quarter reflects increased activity at clinical trial sites as COVID restrictions ease in various jurisdictions.

In Healthcare, 3Q21 revenue was \$1.5m, up 217% on pcp and 76% higher than 2Q21 (as previously noted, revenue in the prior period was restated up from \$0.45m to \$0.48m to reflect the change in revenue recognition policy). The 3Q21 included the recognition of approximately \$1.1m of deferred revenue associated with the Eisai licencing agreement<sup>(1)</sup>, which comprised a full three-month contribution from the Eisai Global (ex Japan) partnership vs 2mths in 2Q21. Cogstate is pleased with the progress being made in its partnership with Eisai. As previously noted, Eisai is committed to launch in the USA within 1 year, the EU within 3 years and China within 4 years.

<sup>(1)</sup> Upfront Eisai Licence Fee cash payments of \$1m received in Sep 19 for Japan and \$15m received in Dec 20 for Global (ex-Japan) to be recognised as revenue on a straight-line basis over the licence periods (10 years for Japan and 6 years for Global (ex-Japan)).


## Sales Contracts Executed

For the quarter ended 31 March 2021, Cogstate executed \$13.3 million of Clinical Trials sales contracts, a record for a 3Q. While this was 7% lower than 2Q21, it was up 24% on the same quarter last year.

During the quarter, Cogstate executed sales contracts with existing customers in addition to first-time agreements with several new customers.

On 23 July 2020, Cogstate announced a preferred partnership with ERT, the global leader in clinical endpoint data collection, that would see Cogstate computerised cognitive assessments deployed in Clinical Trials from ERT's electronic Clinical Outcome Assessment (eCOA) technology platform. During 3Q21 Cogstate was awarded a new contract via the partnership to jointly support a major pharmaceutical sponsor with a global Phase II clinical trial of a candidate therapeutic for the treatment of autoimmune disease. In this study, the Cogstate battery is an exploratory outcome measure deployed from the ERT platform alongside other clinical assessments, providing a unified delivery experience. We expect this partnership to continue to strengthen as we actively advance additional opportunities to jointly support new clinical trials customers with digital cognitive testing solutions across a range of therapeutic indications.

### Clinical Trials Sales Contracts Executed



For context, a history of Clinical Trials sales contracts executed, per quarter, since 1 July 2017 is provided below:

	Sep Quarter US\$m	Dec Quarter US\$m	1 <sup>st</sup> Half US\$m	Mar Quarter US\$m	Jun Quarter US\$m	2 <sup>nd</sup> Half US\$m	Financial Year US\$m
<b>FY21 YTD</b>	\$8.3	\$14.3	\$22.6	\$13.3		N/A	N/A
<b>FY20</b>	\$7.7	\$19.2	\$26.9	\$10.7	\$8.4	\$19.1	\$46.0
<b>FY19</b>	\$5.4	\$4.6	\$10.0	\$3.8	\$4.1	\$7.9	\$17.9
<b>FY18</b>	\$7.5	\$14.1	\$21.6	\$8.3	\$6.2	\$14.5	\$36.1 <sup>(1)</sup>


<sup>(1)</sup> Does not take into account \$6.4m of study cancellations that were recognised at 30 June 2018.

### Contracted Future Revenue

Total Contracted future revenue increased to \$79.7m as at 31 March 21 vs \$74.8m as at 31 Dec 20 and \$42.1m in pcp. The contracted future revenue figure provides insight into future revenue performance of the Group.


In Clinical Trials, contracted future revenue increased during 3Q21 with the value of contracts executed (\$13.3m) exceeding Clinical Trials revenue recognised (\$7.3m). The value of new contracts signed has now exceeded revenue recognised in each of the last 7 consecutive quarters.

### Clinical Trials Sales Contracts vs Revenue Recognised



This has in turn driven a further expansion in the backlog of clinical trials contracted future revenue to a record of US\$55.7m. The graph below shows contracted future revenue as at the end of each half year period since June 2017, as well as the March 2021 quarter:

### Clinical Trials Contracted Future Revenue



Cogstate continues to win work across a number of different indications, but Alzheimer's disease continues to be a significant contributor to new business.

In Healthcare, a further \$24.0m of payments remains to be recognized in relation to the Eisai Global partnerships over the license periods.


The revenue backlog for both the Clinical Trials and Healthcare segments are highlighted in the table below.

Future Backlog Revenue:

	31 Mar 21	31 Dec 20	31 Mar 20
	US\$	US\$	US\$
Contracted Clinical Trials Revenue	55,673,915	49,668,291	42,077,993
Eisai Licence – Global (commercial years 1-5)*	23,191,465	24,224,099	-
Eisai Licence – Japan (10 year licence)	840,268	865,042	-
<b>Total Contracted Future Revenue</b>	<b>79,705,648</b>	<b>74,757,432</b>	<b>42,077,993</b>

\*Minimum royalties for commercial years 6-10 (totalling \$20 million) have not been included due to currently existing termination rights after completion of commercial year 5.

The expected run-off of future revenue backlog is shown in the chart below:



## Operating Cash Flow

- A total cash outflow of  $-\$1.2$  million was reported for the March 2021 quarter, including a net operating cash outflow of  $-\$1.3$  million.
- Cash receipts from customers totalled  $\$6.9$  million for the quarter. With a series of invoices issued late in the quarter, the trade receivables balance increased from  $\$5.5$  million at 31 December 2020 to  $\$7.5$  million at 31 March 2021. Collection of these receivables will benefit cash flow in 4Q21.
- The 3Q21 included the recognition of approximately  $\$1.1$ m of deferred revenue associated with the Eisai licencing agreement. There were no cash payments from the Eisai Global (ex Japan) partnership in the period, these will commence with the earlier of first commercial sale or 12mths (and will equate to a minimum of  $\$10$ m over the initial 5 years).
- Staffing levels and staff costs have remained consistent with prior year. Staff costs of  $\$460$ K have been capitalised for software development and accounted for within cash flows used for investment activities.
- Government grant funds received in the March quarter were nil. The year-to-date Government grant funds ( $\$40,935$ ) relate to the temporary cash flow support provided by the Australian government to small and medium businesses as credits on Business Activity Statements (up to 30 September 2020) lodged as part of COVID-19 support measures

## Related Party Transaction

- As noted in item 6 of the Appendix 4C Cashflow Statement, payments made to related parties and their associates total  $\$94,075$  for the quarter. The payments relate to directors' fees paid to Martyn Myer, David Dolby, Richard Mods, Richard van den Broek, Ingrid Player and Kim Wenn.

## Investing Cash Outflow

- Investing cash outflow of  $\$0.14$  million includes capitalised software development costs of  $\$0.5$  million offset by the receipt of a non-government grant of  $\$0.45$  million.

## Balance Sheet:

- The Company had  $\$17.6$ m net cash as at 31 March 21 (calculated as gross cash less borrowings).
- In May 2020, Cogstate Inc., a US domiciled, wholly owned subsidiary of Cogstate Ltd, secured a US $\$2.44$  million loan from Citibank under the Paycheck Protection Program (PPP) contained within the Coronavirus Aid, Relief and Economic Security (CARES) Act. The application for forgiveness of the PPP loan has been submitted and is pending review.

## FY21 Outlook

- Cogstate recorded a profit before tax during 3Q21 and expects to report a profit before tax for the full year ending 30 June 2021.
- Clinical Trials:
  - Management is encouraged by the increased activity seen at Clinical Trials sites with an easing of COVID restrictions in various offshore jurisdictions.
  - A record backlog of US\$55.7m as at 31 March 2021 augurs well for revenue in future periods.
  - The company will continue to pursue the strengthening pipeline of opportunities with channel partners and opportunities to broaden the reach of Cogstate into clinical trials for a range of diseases.
- Healthcare:
  - Cogstate is pleased with the progress being made in its partnership with Eisai and is focussed on the growth opportunity that the Healthcare market provides.
  - There is an increasing focus on brain health in the community and we have never been closer to a potential disease modifying therapy for Alzheimer's with a number of late-stage potential candidates.

This announcement was authorised for release by the Board of Directors of Cogstate Ltd.

---

### About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW, launched in Japan on 31 March 2020 ([nouknow.jp](http://nouknow.jp)). For more information, please visit [www.cogstate.com](http://www.cogstate.com).

### For further information contact:

Brad O'Connor, Chief Executive Officer, [boconnor@cogstate.com](mailto:boconnor@cogstate.com)

## Quarterly Report – 31 March 2021

### Summary Financial Table

	Quarter Just Completed	Previous Quarter Completed	Previous Corresponding Quarter
	31-Mar-21 US\$ million	31-Dec-20 US\$ million	31-Mar-20 US\$ million
<b>Receivables</b>			
Opening balance	5.49	5.00	4.13
Closing balance	7.45	5.49	7.32
<b>Net Increase/(Decrease) in Receivables</b>	<b>1.96</b>	<b>0.49</b>	<b>3.19</b>
<b>Payables</b>			
Opening balance	(3.78)	(3.41)	(4.53)
Closing balance	(4.29)	(3.78)	(5.04)
<b>Net Increase/(Decrease) in Payables</b>	<b>0.51</b>	<b>0.37</b>	<b>0.51</b>
<b>Cash Flow</b>			
Cash receipts from customers	6.93	22.33	7.23
Cash payments to employees	(5.40)	(4.35)	(5.28)
Cash payments to suppliers	(2.85)	(2.53)	(2.12)
Cash receipts, non-trading	0.00	0.01	0.23
<b>Net Operating Cash In/(Out) Flows</b>	<b>(1.32)</b>	<b>15.46</b>	<b>0.06</b>
<b>Net Investing Cash In/(Out) Flows</b>	<b>(0.14)</b>	<b>(1.37)</b>	<b>(0.12)</b>
<b>Net Financing Cash In/(Out) Flows</b>	<b>0.30</b>	<b>(0.14)</b>	<b>0.21</b>
Foreign exchange movement	-	-	-
<b>Net Increase/(Decrease) in cash held</b>	<b>(1.16)</b>	<b>13.95</b>	<b>0.15</b>



## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Cogstate Limited

**ABN**

80 090 975 723

**Quarter ended ("current quarter")**

31 March 2021

Consolidated statement of cash flows	Current quarter \$US	Year to date (9 months) \$US
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	6,928,597	36,451,359
1.2 Payments for		
(a) research and development	(143)	(1,461)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	13,302	(195,237)
(d) leased assets (refer to 3.9)	-	-
(e) staff costs	(5,399,607)	(14,761,071)
(f) administration and corporate costs*	(2,219,361)	(6,623,868)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	34	128
1.5 Interest and other costs of finance paid	(282)	(37,105)
1.6 Income taxes paid	(3,778)	(811,187)
1.7 Government grants and tax incentives	-	40,935
1.8 Other (provide details if material)		
Grant funds received (non-government)	-	-
Accounting & Audit	(52,973)	(420,932)
Computer costs	(494,969)	(1,189,671)
Advisory fees	-	(375,000)
Legal costs, including patent costs	(39,282)	(112,667)
Listing fees & Associated costs	(37,509)	(85,993)
Travel Costs	(18,501)	29,294
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(1,324,472)</b>	<b>11,907,524</b>

+ See chapter 19 for defined terms.

\*Current quarter includes \$1.8m in clinical trial specific 3<sup>rd</sup> party costs (that are passed through to the customer).

<b>2.</b>	<b>Cash flows from investing activities</b>	-	-
2.1	Payments to acquire:		
	(a) entities		
	(b) businesses	-	-
	(c) property, plant and equipment	(129,015)	(338,368)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) capitalised software development	(460,867)	(2,168,608)
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Grant funds received (non-government – ADDF digital biomarkers grant)	450,000	450,000
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(139,882)</b>	<b>(2,056,976)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>	-	-
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	487,431	607,971
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Principal portion of lease payments	(190,223)	(626,820)
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>297,208</b>	<b>(18,849)</b>

+ See chapter 19 for defined terms.

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>	<b>21,329,622</b>	<b>10,330,777</b>
4.1	Cash and cash equivalents at beginning of period		
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,324,472)	11,907,524
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(139,882)	(2,056,976)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	297,208	(18,849)
4.5	Effect of movement in exchange rates on cash held	-	-
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>20,162,476</b>	<b>20,162,476</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$US</b>	<b>Previous quarter \$US</b>
5.1	Bank balances	20,162,476	21,329,622
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>20,162,476</b>	<b>21,329,622</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter \$US</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	94,075
6.2	Aggregate amount of payments to related parties and their associates included in item 2	Nil

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

Answer:

<b>7. Financing facilities</b>	<b>Total facility amount at quarter end \$US</b>	<b>Amount drawn at quarter end \$US</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>		
<i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities		
7.2 Credit standby arrangements	101,293	71,786
7.3 Other (please specify)		
<b>7.4 Total financing facilities</b>	<b>101,293</b>	<b>71,786</b>

7.5 **Unused financing facilities available at quarter end** **29,507**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Bank Guarantee of US\$67k (A\$88k) in respect to the Melbourne property lease (i.e., 2/255 Bourke Street, Melbourne) and credit card facility of US\$34k (A\$45k).

<b>8. Estimated cash available for future operating activities</b>	<b>\$US</b>
8.1 Net cash from / (used in) operating activities (Item 1.9)	(1,324,472)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	20,162,476
8.3 Unused finance facilities available at quarter end (Item 7.5)	29,507
8.4 Total available funding (Item 8.2 + Item 8.3)	20,191,983
<b>8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)</b>	<b>15.25</b>

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 22 April 2021

Authorised by: David Franks  
Company Secretary

### Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

---

+ See chapter 19 for defined terms.